公开(公告)号：US20230010508A1

公开(公告)日：2023-01-12

申请号：US17773325

申请日：2020-10-29

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

发明人： Ji-Hoon Yu ,  Chun Young lm ,  SoYoung Kim ,  Ye Ri Han ,  Doohyun Lee ,  Hui-Jeon Jeon ,  Sang-Hyun Min ,  Bae Jun Oh ,  Sang-Wook Park ,  Dong-Kyu Choi ,  Young-Kyu Kim ,  Sung Hwan Kim ,  Yuri Lee ,  Seungyeon Lee ,  Nam Hui Kim ,  Sang Bum Kim ,  Ju-Sik Min

IPC分类号： A61K47/55 ,  A61P35/00 ,  A61K47/54

摘要： The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selective protein degradation containing the same as an active ingredient. Since the compound of the present invention can selectively degrade EZH2, it can be effectively used for the treatment of EZH2-related diseases and cancers, particularly, cancers in which EZH2 is overexpressed, and can be usefully used for the selective degradation of EZH2.